메뉴 건너뛰기




Volumn 20, Issue 15, 2014, Pages 4208-4219

Role of cetuximab in first-line treatment of metastatic colorectal cancer

Author keywords

Cetuximab; Colorectal liver metastases; Elderly patients; First line; Metastatic colorectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLFOX; FOLFOX4; FOLFOX6; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; UNCLASSIFIED DRUG; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; LIGAND; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN; TUMOR MARKER; VASCULOTROPIN A;

EID: 84898926844     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i15.4208     Document Type: Article
Times cited : (28)

References (87)
  • 2
    • 34547979071 scopus 로고    scopus 로고
    • Metastatic colorectal cancer-past, progress and future
    • [PMID: 17657834]
    • Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007; 13: 3806-3815 [PMID: 17657834]
    • (2007) World J Gastroenterol , vol.13 , pp. 3806-3815
    • Field, K.1    Lipton, L.2
  • 3
    • 33846592819 scopus 로고    scopus 로고
    • Asymptomatic colorectal cancer with un-resectable liver metastases: Immediate colorectal resection or up-front systemic chemotherapy?
    • [PMID: 17103261 DOI: 10.1245/ s10434-006-9146-1]
    • Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, Capussotti L. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007; 14: 766-770 [PMID: 17103261 DOI: 10.1245/ s10434-006-9146-1]
    • (2007) Ann Surg Oncol , vol.14 , pp. 766-770
    • Muratore, A.1    Zorzi, D.2    Bouzari, H.3    Amisano, M.4    Massucco, P.5    Sperti, E.6    Capussotti, L.7
  • 4
    • 22844443043 scopus 로고    scopus 로고
    • Systemic therapy for metastatic colorectal cancer: Current options, current evidence
    • [PMID: 16002847 DOI: 10.1200/ JCO.2005.17.749]
    • Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553-4560 [PMID: 16002847 DOI: 10.1200/ JCO.2005.17.749]
    • (2005) J Clin Oncol , vol.23 , pp. 4553-4560
    • Kelly, H.1    Goldberg, R.M.2
  • 5
    • 84861325349 scopus 로고    scopus 로고
    • Cetuximab in metastatic colorectal cancer
    • [PMID: 22594891 DOI: 10.1586/era.12.25]
    • Broadbridge VT, Karapetis CS, Price TJ. Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther 2012; 12: 555-565 [PMID: 22594891 DOI: 10.1586/era.12.25]
    • (2012) Expert Rev Anticancer Ther , vol.12 , pp. 555-565
    • Broadbridge, V.T.1    Karapetis, C.S.2    Price, T.J.3
  • 14
    • 34848869989 scopus 로고    scopus 로고
    • Genetic pathways and mutation profiles of human cancers: Site-and exposure-specific patterns
    • [PMID: 17693665 DOI: 10.1093/carcin/bgm176]
    • Lea IA, Jackson MA, Li X, Bailey S, Peddada SD, Dunnick JK. Genetic pathways and mutation profiles of human cancers: site-and exposure-specific patterns. Carcinogenesis 2007; 28: 1851-1858 [PMID: 17693665 DOI: 10.1093/carcin/bgm176]
    • (2007) Carcinogenesis , vol.28 , pp. 1851-1858
    • Lea, I.A.1    Jackson, M.A.2    Li, X.3    Bailey, S.4    Peddada, S.D.5    Dunnick, J.K.6
  • 15
    • 70450195266 scopus 로고    scopus 로고
    • Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
    • [PMID: 19636327 DOI: 10.1038/nrclinonc.2009.111]
    • Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-527 [PMID: 19636327 DOI: 10.1038/nrclinonc.2009.111]
    • (2009) Nat Rev Clin Oncol , vol.6 , pp. 519-527
    • Normanno, N.1    Tejpar, S.2    Morgillo, F.3    De Luca, A.4    Van Cutsem, E.5    Ciardiello, F.6
  • 16
    • 17444403242 scopus 로고    scopus 로고
    • Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
    • [PMID: 15837620 DOI: 10.1016/j.ccr.2005.03.003]
    • Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-311 [PMID: 15837620 DOI: 10.1016/j.ccr.2005.03.003]
    • (2005) Cancer Cell , vol.7 , pp. 301-311
    • Li, S.1    Schmitz, K.R.2    Jeffrey, P.D.3    Wiltzius, J.J.4    Kussie, P.5    Ferguson, K.M.6
  • 17
    • 33646355483 scopus 로고    scopus 로고
    • New issues on cetuximab mechanism of action in epidermal growth factor receptornegative colorectal cancer: The role of vascular endothelial growth factor
    • author reply, [PMID: 16622275 DOI: 10.1200/JCO.2005.05.0450]
    • Vincenzi B, Santini D, Tonini G. New issues on cetuximab mechanism of action in epidermal growth factor receptornegative colorectal cancer: the role of vascular endothelial growth factor. J Clin Oncol 2006; 24: author reply 1957-1958 [PMID: 16622275 DOI: 10.1200/JCO.2005.05.0450]
    • (2006) J Clin Oncol , vol.24 , pp. 1957-1958
    • Vincenzi, B.1    Santini, D.2    Tonini, G.3
  • 18
    • 47149084688 scopus 로고    scopus 로고
    • Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer
    • [PMID: 18503402 DOI: 10.1592/phco.28.6.742]
    • Jean GW, Shah SR. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008; 28: 742-754 [PMID: 18503402 DOI: 10.1592/phco.28.6.742]
    • (2008) Pharmacotherapy , vol.28 , pp. 742-754
    • Jean, G.W.1    Shah, S.R.2
  • 21
    • 79956310674 scopus 로고    scopus 로고
    • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study
    • [PMID: 21228335 DOI: 10.1093/annonc/mdq632]
    • Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-1546 [PMID: 21228335 DOI: 10.1093/annonc/mdq632]
    • (2011) Ann Oncol , vol.22 , pp. 1535-1546
    • Bokemeyer, C.1    Bondarenko, I.2    Hartmann, J.T.3    de Braud, F.4    Schuch, G.5    Zubel, A.6    Celik, I.7    Schlichting, M.8    Koralewski, P.9
  • 24
    • 84862026304 scopus 로고    scopus 로고
    • Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
    • [PMID: 22446022 DOI: 10.1016/ j.ejca.2012.02.057]
    • Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne CH. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-1475 [PMID: 22446022 DOI: 10.1016/ j.ejca.2012.02.057]
    • (2012) Eur J Cancer , vol.48 , pp. 1466-1475
    • Bokemeyer, C.1    Van Cutsem, E.2    Rougier, P.3    Ciardiello, F.4    Heeger, S.5    Schlichting, M.6    Celik, I.7    Köhne, C.H.8
  • 25
    • 73349114941 scopus 로고    scopus 로고
    • KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial
    • [PMID: 19884549 DOI: 10.1200/ JCO.2009.22.4295]
    • Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-5937 [PMID: 19884549 DOI: 10.1200/ JCO.2009.22.4295]
    • (2009) J Clin Oncol , vol.27 , pp. 5931-5937
    • Richman, S.D.1    Seymour, M.T.2    Chambers, P.3    Elliott, F.4    Daly, C.L.5    Meade, A.M.6    Taylor, G.7    Barrett, J.H.8    Quirke, P.9
  • 26
    • 58249089525 scopus 로고    scopus 로고
    • CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
    • [PMID: 18832519 DOI: 10.1136/gut.2008.155473]
    • Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96 [PMID: 18832519 DOI: 10.1136/gut.2008.155473]
    • (2009) Gut , vol.58 , pp. 90-96
    • Ogino, S.1    Nosho, K.2    Kirkner, G.J.3    Kawasaki, T.4    Meyerhardt, J.A.5    Loda, M.6    Giovannucci, E.L.7    Fuchs, C.S.8
  • 27
    • 79957523828 scopus 로고    scopus 로고
    • KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
    • [PMID: 21163703 DOI: 10.1016/S1470-2045(10)70209-6]
    • De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603 [PMID: 21163703 DOI: 10.1016/S1470-2045(10)70209-6]
    • (2011) Lancet Oncol , vol.12 , pp. 594-603
    • De Roock, W.1    De Vriendt, V.2    Normanno, N.3    Ciardiello, F.4    Tejpar, S.5
  • 29
    • 84896121177 scopus 로고    scopus 로고
    • Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients (Sep 27-Oct 1, 2013; Amsterdam, The Netherlands)
    • abstract 17
    • Stintzing S, Jung A, Rossius L, Modest DP, Fischer von Weikersthal L, Decker T, Möhler M, Scheithauer W, Kirchner T, Heinemann V. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients (Sep 27-Oct 1, 2013; Amsterdam, The Netherlands). European Cancer Congress 2013; 2013: abstract 17
    • (2013) European Cancer Congress , vol.2013
    • Stintzing, S.1    Jung, A.2    Rossius, L.3    Modest, D.P.4    von Weikersthal Fischer, L.5    Decker, T.6    Möhler, M.7    Scheithauer, W.8    Kirchner, T.9    Heinemann, V.10
  • 31
    • 84902544715 scopus 로고    scopus 로고
    • Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT
    • on behalf of Italian Trials in Medical Oncology (ITMO) Group, Jul 3; Epub ahead of print [PMID: 23821376 DOI: 10.1007/s11523-013-0283-8]
    • Di Bartolomeo M, Pietrantonio F, Perrone F, Dotti KF, Lampis A, Bertan C, Beretta E, Rimassa L, Carbone C, Biondani P, Passalacqua R, Pilotti S, Bajetta E; on behalf of Italian Trials in Medical Oncology (ITMO) Group. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Target Oncol 2013 Jul 3; Epub ahead of print [PMID: 23821376 DOI: 10.1007/s11523-013-0283-8]
    • (2013) Target Oncol
    • Di Bartolomeo, M.1    Pietrantonio, F.2    Perrone, F.3    Dotti, K.F.4    Lampis, A.5    Bertan, C.6    Beretta, E.7    Rimassa, L.8    Carbone, C.9    Biondani, P.10    Passalacqua, R.11    Pilotti, S.12    Bajetta, E.13
  • 33
    • 2142641698 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    • [PMID: 14993230 DOI: 10.1200/JCO.2004.10.182]
    • Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208 [PMID: 14993230 DOI: 10.1200/JCO.2004.10.182]
    • (2004) J Clin Oncol , vol.22 , pp. 1201-1208
    • Saltz, L.B.1    Meropol, N.J.2    Loehrer, P.J.3    Needle, M.N.4    Kopit, J.5    Mayer, R.J.6
  • 37
    • 33644697486 scopus 로고    scopus 로고
    • Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
    • [PMID: 16303861 DOI: 10.1093/annonc/mdj084]
    • Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH. Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450-456 [PMID: 16303861 DOI: 10.1093/annonc/mdj084]
    • (2006) Ann Oncol , vol.17 , pp. 450-456
    • Folprecht, G.1    Lutz, M.P.2    Schöffski, P.3    Seufferlein, T.4    Nolting, A.5    Pollert, P.6    Köhne, C.H.7
  • 38
    • 65649086838 scopus 로고    scopus 로고
    • Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: A multicentre two-part phase I/II study
    • [PMID: 19366444 DOI: 10.1186/1471-2407-9-112]
    • Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009; 9: 112 [PMID: 19366444 DOI: 10.1186/1471-2407-9-112]
    • (2009) BMC Cancer , vol.9 , pp. 112
    • Raoul, J.L.1    Van Laethem, J.L.2    Peeters, M.3    Brezault, C.4    Husseini, F.5    Cals, L.6    Nippgen, J.7    Loos, A.H.8    Rougier, P.9
  • 39
    • 84869869929 scopus 로고    scopus 로고
    • Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (mCRC): Analysis from the CRYSTAL study
    • [DOI: 10.1093/annonc/mdq521]
    • Piessevaux H, Schlichting M, Heeger S, Van Cutsem E, Tejpar S. Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (mCRC): analysis from the CRYSTAL study. Ann Oncol 2010; 21 Suppl 8: viii189-viii224 [DOI: 10.1093/annonc/mdq521]
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL. 8
    • Piessevaux, H.1    Schlichting, M.2    Heeger, S.3    Van Cutsem, E.4    Tejpar, S.5
  • 40
    • 84870843463 scopus 로고    scopus 로고
    • Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): Assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies
    • abstr 3572
    • Piessevaux H, Van Cutsem E, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): Assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies. J Clin Oncol (ASCO Meeting Abstracts) 2011; 29 Suppl: abstr 3572
    • (2011) J Clin Oncol (ASCO Meeting Abstracts) , vol.29 , Issue.SUPPL.
    • Piessevaux, H.1    Van Cutsem, E.2    Bokemeyer, C.3    Schlichting, M.4    Heeger, S.5    Tejpar, S.6
  • 42
    • 84893651149 scopus 로고    scopus 로고
    • Quantitative analysis of the impact of deepness of response on postprogression survival time following first-line treatment in patients with mCRC
    • abstr 3630
    • Mansmann UR, Sartorius U, Laubender RP, Giessen CA, Esser R, Heinemann V. Quantitative analysis of the impact of deepness of response on postprogression survival time following first-line treatment in patients with mCRC. J Clin Oncol (ASCO Meeting Abstracts) 2013; 31 Suppl: abstr 3630
    • (2013) J Clin Oncol (ASCO Meeting Abstracts) , vol.31 , Issue.SUPPL.
    • Mansmann, U.R.1    Sartorius, U.2    Laubender, R.P.3    Giessen, C.A.4    Esser, R.5    Heinemann, V.6
  • 43
    • 84893673381 scopus 로고    scopus 로고
    • Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC
    • [DOI: 10.1093/annonc/mdt201.9]
    • Mansmann U, Sartorius U, Laubender R, Giessen C, Esser R, Heinemann V. Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC. Ann Oncol 2013; 24 Suppl 4: iv14-iv15 [DOI: 10.1093/annonc/mdt201.9]
    • (2013) Ann Oncol , vol.24 , Issue.SUPPL. 4
    • Mansmann, U.1    Sartorius, U.2    Laubender, R.3    Giessen, C.4    Esser, R.5    Heinemann, V.6
  • 45
    • 21344437283 scopus 로고    scopus 로고
    • Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
    • [PMID: 15890668 DOI: 10.1093/annonc/mdi196]
    • Punt CJ. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer? Ann Oncol 2005; 16: 845-846 [PMID: 15890668 DOI: 10.1093/annonc/mdi196]
    • (2005) Ann Oncol , vol.16 , pp. 845-846
    • Punt, C.J.1
  • 48
    • 48749119784 scopus 로고    scopus 로고
    • Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: A phase Ib/II study of the AIO GI Group
    • [PMID: 18441330 DOI: 10.1093/annonc/mdn150]
    • Arnold D, Höhler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Wöll E, Herrmann T, Zubel A, Schmoll HJ. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008; 19: 1442-1449 [PMID: 18441330 DOI: 10.1093/annonc/mdn150]
    • (2008) Ann Oncol , vol.19 , pp. 1442-1449
    • Arnold, D.1    Höhler, T.2    Dittrich, C.3    Lordick, F.4    Seufferlein, T.5    Riemann, J.6    Wöll, E.7    Herrmann, T.8    Zubel, A.9    Schmoll, H.J.10
  • 51
    • 33645749886 scopus 로고    scopus 로고
    • In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR
    • [PMID: 16320055 DOI: 10.1007/s00280-005-0123-3]
    • Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 2006; 57: 709-718 [PMID: 16320055 DOI: 10.1007/s00280-005-0123-3]
    • (2006) Cancer Chemother Pharmacol , vol.57 , pp. 709-718
    • Balin-Gauthier, D.1    Delord, J.P.2    Rochaix, P.3    Mallard, V.4    Thomas, F.5    Hennebelle, I.6    Bugat, R.7    Canal, P.8    Allal, C.9
  • 52
    • 37549007196 scopus 로고    scopus 로고
    • Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab
    • [PMID: 18094427 DOI: 10.1158/1078-0432.CCR-07-1768]
    • Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, Hicklin DJ, Tonra JR. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res 2007; 13: 7432-7440 [PMID: 18094427 DOI: 10.1158/1078-0432.CCR-07-1768]
    • (2007) Clin Cancer Res , vol.13 , pp. 7432-7440
    • Prewett, M.1    Deevi, D.S.2    Bassi, R.3    Fan, F.4    Ellis, L.M.5    Hicklin, D.J.6    Tonra, J.R.7
  • 53
    • 38049045220 scopus 로고    scopus 로고
    • Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation
    • [PMID: 18182978 DOI: 10.1038/sj.bjc.6604134]
    • Balin-Gauthier D, Delord JP, Pillaire MJ, Rochaix P, Hoffman JS, Bugat R, Cazaux C, Canal P, Allal BC. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 2008; 98: 120-128 [PMID: 18182978 DOI: 10.1038/sj.bjc.6604134]
    • (2008) Br J Cancer , vol.98 , pp. 120-128
    • Balin-Gauthier, D.1    Delord, J.P.2    Pillaire, M.J.3    Rochaix, P.4    Hoffman, J.S.5    Bugat, R.6    Cazaux, C.7    Canal, P.8    Allal, B.C.9
  • 54
    • 84878014791 scopus 로고    scopus 로고
    • Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer
    • [PMID: 23504768 DOI: 10.1002/cncr.27994]
    • Woo J, Palmisiano N, Tester W, Leighton JC. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer 2013; 119: 1941-1950 [PMID: 23504768 DOI: 10.1002/cncr.27994]
    • (2013) Cancer , vol.119 , pp. 1941-1950
    • Woo, J.1    Palmisiano, N.2    Tester, W.3    Leighton, J.C.4
  • 57
    • 84867877541 scopus 로고    scopus 로고
    • Liver resection for multiple colorectal liver metastases with surgery up-front approach: Bi-institutional analysis of 736 consecutive cases
    • [PMID: 22547015 DOI: 10.1007/s00268-012-1616-y]
    • Saiura A, Yamamoto J, Hasegawa K, Koga R, Sakamoto Y, Hata S, Makuuchi M, Kokudo N. Liver resection for multiple colorectal liver metastases with surgery up-front approach: bi-institutional analysis of 736 consecutive cases. World J Surg 2012; 36: 2171-2178 [PMID: 22547015 DOI: 10.1007/s00268-012-1616-y]
    • (2012) World J Surg , vol.36 , pp. 2171-2178
    • Saiura, A.1    Yamamoto, J.2    Hasegawa, K.3    Koga, R.4    Sakamoto, Y.5    Hata, S.6    Makuuchi, M.7    Kokudo, N.8
  • 60
    • 4644320061 scopus 로고    scopus 로고
    • Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival
    • discussion 657-658, [PMID: 15383792 DOI: 10.1097/01. sla.0000141198.92114.f6]
    • Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657; discussion 657-658 [PMID: 15383792 DOI: 10.1097/01. sla.0000141198.92114.f6]
    • (2004) Ann Surg , vol.240 , pp. 644-657
    • Adam, R.1    Delvart, V.2    Pascal, G.3    Valeanu, A.4    Castaing, D.5    Azoulay, D.6    Giacchetti, S.7    Paule, B.8    Kunstlinger, F.9    Ghémard, O.10    Levi, F.11    Bismuth, H.12
  • 61
    • 2642541197 scopus 로고    scopus 로고
    • Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients
    • [PMID: 15151951 DOI: 10.1093/annonc/mdh217]
    • Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-939 [PMID: 15151951 DOI: 10.1093/annonc/mdh217]
    • (2004) Ann Oncol , vol.15 , pp. 933-939
    • Pozzo, C.1    Basso, M.2    Cassano, A.3    Quirino, M.4    Schinzari, G.5    Trigila, N.6    Vellone, M.7    Giuliante, F.8    Nuzzo, G.9    Barone, C.10
  • 62
    • 33644819672 scopus 로고    scopus 로고
    • Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study
    • [PMID: 16230673 DOI: 10.1200/JCO.2005.07.740]
    • Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23: 9243-9249 [PMID: 16230673 DOI: 10.1200/JCO.2005.07.740]
    • (2005) J Clin Oncol , vol.23 , pp. 9243-9249
    • Alberts, S.R.1    Horvath, W.L.2    Sternfeld, W.C.3    Goldberg, R.M.4    Mahoney, M.R.5    Dakhil, S.R.6    Levitt, R.7    Rowland, K.8    Nair, S.9    Sargent, D.J.10    Donohue, J.H.11
  • 63
    • 33748101222 scopus 로고    scopus 로고
    • Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
    • [PMID: 16904315 DOI: 10.1016/j.ejca.2006.04.012]
    • Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221 [PMID: 16904315 DOI: 10.1016/j.ejca.2006.04.012]
    • (2006) Eur J Cancer , vol.42 , pp. 2212-2221
    • Van Cutsem, E.1    Nordlinger, B.2    Adam, R.3    Köhne, C.H.4    Pozzo, C.5    Poston, G.6    Ychou, M.7    Rougier, P.8
  • 65
    • 34247556508 scopus 로고    scopus 로고
    • Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy
    • [PMID: 17458605 DOI: 10.1007/s11605-006-0070-2]
    • Nuzzo G, Giuliante F, Ardito F, Vellone M, Pozzo C, Cassano A, Giovannini I, Barone C. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 2007; 11: 318-324 [PMID: 17458605 DOI: 10.1007/s11605-006-0070-2]
    • (2007) J Gastrointest Surg , vol.11 , pp. 318-324
    • Nuzzo, G.1    Giuliante, F.2    Ardito, F.3    Vellone, M.4    Pozzo, C.5    Cassano, A.6    Giovannini, I.7    Barone, C.8
  • 66
    • 64649092523 scopus 로고    scopus 로고
    • Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure?
    • [PMID: 19273699 DOI: 10.1200/JCO.2008.19.9273]
    • Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27: 1829-1835 [PMID: 19273699 DOI: 10.1200/JCO.2008.19.9273]
    • (2009) J Clin Oncol , vol.27 , pp. 1829-1835
    • Adam, R.1    Wicherts, D.A.2    de Haas, R.J.3    Ciacio, O.4    Lévi, F.5    Paule, B.6    Ducreux, M.7    Azoulay, D.8    Bismuth, H.9    Castaing, D.10
  • 68
    • 84873509118 scopus 로고    scopus 로고
    • Progression free and overall survival after neoadjuvant treatment of colorectal liver metastases with cetuximab plus FOLFOX or FOLFIRI-Results of the CELIM study
    • [DOI: 10.1016/ S0959-8049(11)71654-9]
    • Folprecht G, Gruenberger T, Bechstein W, Lordick T, Lang H, Weitz J, Suedhoff T, Hartmann J, Liersch T, Koehne C. Progression free and overall survival after neoadjuvant treatment of colorectal liver metastases with cetuximab plus FOLFOX or FOLFIRI-Results of the CELIM study. Eur J Cancer 2011; 47 Suppl 1: S394 [DOI: 10.1016/ S0959-8049(11)71654-9]
    • (2011) Eur J Cancer , vol.47 , Issue.SUPPL. 1
    • Folprecht, G.1    Gruenberger, T.2    Bechstein, W.3    Lordick, T.4    Lang, H.5    Weitz, J.6    Suedhoff, T.7    Hartmann, J.8    Liersch, T.9    Koehne, C.10
  • 70
    • 84880736194 scopus 로고    scopus 로고
    • Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wildtype unresectable colorectal liver-limited metastases
    • [PMID: 23569301 DOI: 10.1200/ JCO.2012.44.8308]
    • Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wildtype unresectable colorectal liver-limited metastases. J Clin Oncol 2013; 31: 1931-1938 [PMID: 23569301 DOI: 10.1200/ JCO.2012.44.8308]
    • (2013) J Clin Oncol , vol.31 , pp. 1931-1938
    • Ye, L.C.1    Liu, T.S.2    Ren, L.3    Wei, Y.4    Zhu, D.X.5    Zai, S.Y.6    Ye, Q.H.7    Yu, Y.8    Xu, B.9    Qin, X.Y.10    Xu, J.11
  • 71
    • 23844448040 scopus 로고    scopus 로고
    • Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates
    • [PMID: 15870084 DOI: 10.1093/annonc/mdi246]
    • Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319 [PMID: 15870084 DOI: 10.1093/annonc/mdi246]
    • (2005) Ann Oncol , vol.16 , pp. 1311-1319
    • Folprecht, G.1    Grothey, A.2    Alberts, S.3    Raab, H.R.4    Köhne, C.H.5
  • 73
    • 78149469673 scopus 로고    scopus 로고
    • Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
    • [PMID: 20959822 DOI: 10.1038/sj.bjc.6605940]
    • Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vennarecci G, Mottolese M, Sperduti I, Cognetti F. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010; 103: 1542-1547 [PMID: 20959822 DOI: 10.1038/sj.bjc.6605940]
    • (2010) Br J Cancer , vol.103 , pp. 1542-1547
    • Garufi, C.1    Torsello, A.2    Tumolo, S.3    Ettorre, G.M.4    Zeuli, M.5    Campanella, C.6    Vennarecci, G.7    Mottolese, M.8    Sperduti, I.9    Cognetti, F.10
  • 74
  • 75
    • 84870785743 scopus 로고    scopus 로고
    • A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: A pilot phase II trial
    • [PMID: 23169296 DOI: 10.1038/bjc.2012.509]
    • Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V, Souglakos J. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer 2012; 107: 1932-1937 [PMID: 23169296 DOI: 10.1038/bjc.2012.509]
    • (2012) Br J Cancer , vol.107 , pp. 1932-1937
    • Saridaki, Z.1    Androulakis, N.2    Vardakis, N.3    Vamvakas, L.4    Kabouraki, E.5    Kalbakis, K.6    Hatzidaki, D.7    Voutsina, A.8    Mavroudis, D.9    Georgoulias, V.10    Souglakos, J.11
  • 76
    • 0033920730 scopus 로고    scopus 로고
    • Management of cancer in the older person: A practical approach
    • [PMID: 10884501 DOI: 10.1634/theoncologist.5-3-224]
    • Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000; 5: 224-237 [PMID: 10884501 DOI: 10.1634/theoncologist.5-3-224]
    • (2000) Oncologist , vol.5 , pp. 224-237
    • Balducci, L.1    Extermann, M.2
  • 77
    • 12244298248 scopus 로고    scopus 로고
    • Colorectal cancer in the elderly: Is palliative chemotherapy of value?
    • [PMID: 12513112]
    • Honecker F, Köhne CH, Bokemeyer C. Colorectal cancer in the elderly: is palliative chemotherapy of value? Drugs Aging 2003; 20: 1-11 [PMID: 12513112]
    • (2003) Drugs Aging , vol.20 , pp. 1-11
    • Honecker, F.1    Köhne, C.H.2    Bokemeyer, C.3
  • 78
    • 20644437768 scopus 로고    scopus 로고
    • Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study
    • [PMID: 15908665 DOI: 10.1200/JCO.2005.03.004]
    • Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Antón A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Díaz-Rubio E. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005; 23: 3545-3551 [PMID: 15908665 DOI: 10.1200/JCO.2005.03.004]
    • (2005) J Clin Oncol , vol.23 , pp. 3545-3551
    • Sastre, J.1    Marcuello, E.2    Masutti, B.3    Navarro, M.4    Gil, S.5    Antón, A.6    Abad, A.7    Aranda, E.8    Maurel, J.9    Valladares, M.10    Maestu, I.11    Carrato, A.12    Vicent, J.M.13    Díaz-Rubio, E.14
  • 80
    • 4143089333 scopus 로고    scopus 로고
    • Predictive factors of survival in patients with advanced colorectal cancer: An individual data analysis of 602 patients included in irinotecan phase III trials
    • [PMID: 15205193 DOI: 10.1093/annonc/mdh267]
    • Mitry E, Douillard JY, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L, Rougier P. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004; 15: 1013-1017 [PMID: 15205193 DOI: 10.1093/annonc/mdh267]
    • (2004) Ann Oncol , vol.15 , pp. 1013-1017
    • Mitry, E.1    Douillard, J.Y.2    Van Cutsem, E.3    Cunningham, D.4    Magherini, E.5    Mery-Mignard, D.6    Awad, L.7    Rougier, P.8
  • 81
    • 33748669385 scopus 로고    scopus 로고
    • Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
    • [PMID: 16943526 DOI: 10.1200/JCO.2006.06.9039]
    • Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091 [PMID: 16943526 DOI: 10.1200/JCO.2006.06.9039]
    • (2006) J Clin Oncol , vol.24 , pp. 4085-4091
    • Goldberg, R.M.1    Tabah-Fisch, I.2    Bleiberg, H.3    de Gramont, A.4    Tournigand, C.5    Andre, T.6    Rothenberg, M.L.7    Green, E.8    Sargent, D.J.9
  • 83
    • 67649201009 scopus 로고    scopus 로고
    • Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: Findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study
    • [PMID: 19382200 DOI: 10.1002/cncr.24305]
    • Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, Meyerhardt J. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 2009; 115: 2617-2629 [PMID: 19382200 DOI: 10.1002/cncr.24305]
    • (2009) Cancer , vol.115 , pp. 2617-2629
    • Jackson, N.A.1    Barrueco, J.2    Soufi-Mahjoubi, R.3    Marshall, J.4    Mitchell, E.5    Zhang, X.6    Meyerhardt, J.7
  • 85
    • 84856434000 scopus 로고    scopus 로고
    • Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
    • [PMID: 22215062 DOI: 10.1038/bjc.2011.554]
    • Jehn CF, Böning L, Kröning H, Possinger K, Lüftner D. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer 2012; 106: 274-278 [PMID: 22215062 DOI: 10.1038/bjc.2011.554]
    • (2012) Br J Cancer , vol.106 , pp. 274-278
    • Jehn, C.F.1    Böning, L.2    Kröning, H.3    Possinger, K.4    Lüftner, D.5
  • 86
    • 78650309129 scopus 로고    scopus 로고
    • First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)
    • [PMID: 20042346 DOI: 10.1016/j.critrevonc.2009.11.005]
    • Sastre J, Aranda E, Grávalos C, Massutí B, Varella-Garcia M, Rivera F, Soler G, Carrato A, Manzano JL, Díaz-Rubio E, Hidalgo M. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 2011; 77: 78-84 [PMID: 20042346 DOI: 10.1016/j.critrevonc.2009.11.005]
    • (2011) Crit Rev Oncol Hematol , vol.77 , pp. 78-84
    • Sastre, J.1    Aranda, E.2    Grávalos, C.3    Massutí, B.4    Varella-Garcia, M.5    Rivera, F.6    Soler, G.7    Carrato, A.8    Manzano, J.L.9    Díaz-Rubio, E.10    Hidalgo, M.11
  • 87
    • 84859412772 scopus 로고    scopus 로고
    • Progression free and overall survival after neoadjuvant treatment of colorectal liver metastases with cetuximab plus FOLFOX or FOLFIRI-Results of the CELIM study
    • [PMID: 22363067 DOI: 10.1634/theoncologist. 2011-0406]
    • Folprecht G, Gruenberger T, Bechstein W, Lordick T, Lang H, Weitz J, Suedhoff T, Hartmann J, Liersch T, Koehne C. Progression free and overall survival after neoadjuvant treatment of colorectal liver metastases with cetuximab plus FOLFOX or FOLFIRI-Results of the CELIM study. Oncologist 2012; 17: 339-345 [PMID: 22363067 DOI: 10.1634/theoncologist. 2011-0406]
    • (2012) Oncologist , vol.17 , pp. 339-345
    • Folprecht, G.1    Gruenberger, T.2    Bechstein, W.3    Lordick, T.4    Lang, H.5    Weitz, J.6    Suedhoff, T.7    Hartmann, J.8    Liersch, T.9    Koehne, C.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.